FHFrank Hanisch

Frank Hanisch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Frank Hanisch has a total of 122 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • C-Reactive Protein in Idiopathic Inflammatory Myopathies

    by Frank Hanisch, Stephan Zierz

    Objectives: To characterize C-reactive protein [CRP] in polymyositis [PM], dermatomyositis [DM], Jo-1 syndrome [Jo-1] and sporadic inclusion body myositis [sIBM]. Methods: C-reactive protein obtained before the start of immunosuppressive therapy was analyzed retrospectively in 61 therapy naïve patients [PM n = 27, DM n = 15, Jo-1 n = 5, sIBM n = 14]. All patients had a diagnosis of idiopathic inflammatory myopathy confirmed by muscle biopsy. Results: C-reactive protein was significantly higher in DM and Jo-1 compared to PM and sIBM [ANOVA p < 0.001]. The CRP levels less than twice the upper limit were found in 79% of sIBM patients, 85% of PM patients, 20% Jo-1 of patients, 53% of DM patients. C-reactive protein showed no correlation with creatine kinase and erythrocyte sedimentation rate. Conclusions: The CRP is elevated in a minority of patients with myositis, mostly associated with interstitial lung disease and malignancies.


  • Characterization of monoclonal gammopathy in patients with amyotrophic lateral sclerosis

    by H.-H. Wolf, A. Posa, S. Panitz, M. Kornhuber, F. Hanisch

    Recently, new guidelines for the monitoring and the risk evaluation of monoclonal gammopathy with undetermined significance (MGUS) became available and the light chain MGUS subtype was defined. To characterize the type, risk and diagnostic implications of MGUS in patients with amyotrophic lateral sclerosis. We screened 97 consecutive patients with ALS and 97 age- and gender-matched controls for MGUS by serum electrophoresis and immunofixation and compared the characteristics of MGUS with population-based data. MGUS was identified in 8.2% of ALS patients and 6.2% of controls (mean age: 62.5 years both). Seven of eight ALS patients with MGUS had 'low-risk MGUS'. M-protein was moderately increased in one ALS patient. The immunoglobulin distribution in ALS patients with MGUS was IgG kappa (n = 2), IgM lambda (n = 1) and light chains of lambda type (n = 3). No differences in demographic and clinical parameters were found between patients with and without MGUS. The percentage of patients with MGUS is increased in ALS, but the immunoglobulin distribution is similar to that reported in the general population. MGUS in ALS mostly represents 'low-risk MGUS'; therefore, unnecessary diagnostic procedures should be avoided in ALS patients.


  • Open Access

    Characteristics of pain in amyotrophic lateral sclerosis

    by Frank Hanisch, Anika Skudlarek, Janine Berndt, Malte E. Kornhuber

    Background: Pain is an often underestimated and neglected symptom in amyotrophic lateral sclerosis (ALS).Methods: In a cross‐sectional survey, 46 patients with ALS, 46 age‐ and gender matched population‐based controls, and 23 diseased controls with myotonic dystrophy type 2 (DM2) were screened for occurrence, type, distribution, and treatment of pain and cramps. Data were collected with the use of the short form brief pain inventory (BPI).Results: Pain was reported in 78% of ALS patients,79% of DM2 patients, and 54% of controls (P < 0.05). More ALS patients than controls reported moderate to severe pain (42% vs. 20%). Pain in ALS patients interfered significantly more with daily activities than in controls (median pain interference score: 3.0 vs. 1.2, P < 0.05), especially enjoyment of life (5.0 vs. 1.0) and mood (3.0 vs. 1.0). There was no correlation between the duration of the disease and the severity of pain. Movement‐induced cramps were reported in 63% of ALS patients, mostly in the distal extremities. There was no difference in the duration of ALS disease between patients reporting cramps and those who did not.Discussion: Our study showed that pain was a relatively frequent symptom which had an important impact on the quality of life. Pain that requires treatment can occur at every stage of ALS.


  • The checklist individual strength (CIS20-R) in patients with amyotrophic lateral sclerosis - A longitudinal study

    by S. Panitz, M. Kornhuber, F. Hanisch

    Fatigue may be underestimated symptom in amyotrophic lateral sclerosis (ALS). The self-administered checklist individual strength (CIS20-R) was used to measure both physical and mental fatigue in ALS. Fatigue was measured in 51 consecutive patients with ALS using the fatigue severity scale (FSS) and the CIS20-R (four dimensions: subjective fatigue experience, concentration, motivation, activity). The questionnaire scores were compared with disease and progression parameters [revised ALS functional rating scale (ALS-FRS-R), MRC sum score, slow vital capacity (slow VC)]. Patients had follow-ups at six and 12 months. At baseline (mean age: 57.9 years ± 12.3, mean disease duration: 15.8 months ± 12.7) clinical relevant fatigue was seen in 49% in FSS and 40% in CIS20-R. FSS and CIS20-R (except the subscale for concentration) were steadily increasing in the course of the disease. CIS1 (subjective fatigue) but not FSS showed a correlation to the ALS-FRS-R and the progression of the ALS-FRS-R after 12 months. There was a moderate positive correlation between FSS and CIS20-R. The CIS20-R is a sensitive tool to detect clinically relevant fatigue in early stages of ALS. Both physical and mental (motivation) dimensions of fatigue steadily increase during the course of the disease in ALS.


  • Urge Incontinence and Gastrointestinal Symptoms in Adult Patients with Pompe Disease: A Cross-Sectional Survey

    by Nesrin Karabul, Anika Skudlarek, Janine Berndt, Cornelia Kornblum, Rudolf A. Kley, Stephan Wenninger, Nikolaus Tiling, Eugen Mengel, Ursula Plöckinger, Matthias Vorgerd, et al.

    Objective: To determine the frequency and impact of gastrointestinal symptoms, and bowel and urinary incontinence, as this is currently unknown in adults with Pompe disease. Methods: Adult German Pompe patients and age- and gender-matched controls were asked about symptoms in the upper and lower intestinal tract as well as urinary incontinence using the Gastrointestinal Symptoms Questionnaire and the International Consultation on Incontinence Questionnaires for Bowel Symptoms and Urinary Incontinence. Results: The overall response rate was 78%; 57 patients and 57 controls participated. The mean age of the patients was 48.3 years ±14.7 (28 female, 29 male). 84% of patients were receiving enzyme replacement therapy. Stool urgency, diarrhoea, and urinary urge incontinence were reported significantly more frequently in patients compared to the age- and gender-matched controls (55%, 56%, 33% vs. 20%, 18%, 7%). 20% of Pompe patients used loperamide daily against diarrhoea. No other gastrointestinal tract-related symptoms were reported to occur more frequently in Pompe patients than in controls. Conclusions: Compared to age- and gender-matched controls, both urinary and bowel incontinence occur in a higher frequency in adults with Pompe disease and have a major impact on daily life.


  • The significance of pathological spontaneous activity in various myopathies

    by F. Hanisch, C. Kronenberger, S. Zierz, M. Kornhuber


  • Pregnancy and delivery in women with Pompe disease

    by Nesrin Karabul, Janine Berndt, Cornelia Kornblum, Rudolf A. Kley, S. Wenninger, Nikolaus Tiling, Eugen Mengel, Ursula Plöckinger, Matthias Vorgerd, Marcus Deschauer, et al.


  • Dilatation der hirnversorgenden Arterien bei Patienten mit adultem M. Pompe

    by O Hensel, F Hanisch, T Müller

    Einleitung: Die Glykogenose Typ II (Morbus Pompe) ist eine lysosomale Speicherkrankheit verursacht durch eine Mutation im GAA Gen, dass das Enzym Alpha-Glukosidase kodiert. Charakteristisch ist die intrazelluläre Glykogenspeicherung insbesondere in der quergestreiften Muskulatur, aber auch in der glatten Gefäßmuskulatur (Winkel et al. 2003). Fallberichte über fusiforme Aneurysmen an den Hirnbasisgefäßen und intrakranielle Blutungen legen nahe, dass die zu Grunde liegende Gefäßpathologie Folge der Glykogenablagerungen in der Gefäßmuskulatur ist (Laforêt et al. 2008, Sacconi et al. 2010, Lilleker et al. 2013). Wir konnten bisher zeigen, dass die Durchmesser der Hirnbasisgefäße von Patienten mit adulter Pompe-Erkrankung ohne zerebrovaskuläre Vorerkrankungen dilatiert sind (submitted). Die Dilatation der thorakalen Aorta wurde ebenfalls beschrieben (El-Gharbawy 2011). Wir untersuchten jetzt, ob weitere extrakranielle Arterien wie die A. carotis communis dilatiert sind. Methoden: 10 Patienten mit genetisch nachgewiesener adulter Pompe-Erkrankung (Alter 46 ± 12 Jahre, 5 Frauen) ohne zerebrovaskuläre Vorerkrankungen wurden eingeschlossen. Der Durchmesser der A. carotis communis wurde duplexsonographisch mindestens 1 cm vor dem Bulbus caroticus im B-Bild bestimmt. Die maximalen Durchmesser der Aa. vertebrales, A. basilaris, Aa. cerebri mediae, anteriores und posteriores, der Aa. carotides internae sowie der Durchmesser des distalen M1-Segmentes der Aa. cerebri mediae wurden in einer Voruntersuchung gd-MR-angiographisch bestimmt. Zum Vergleich wurden 24 MR-Angiografien und 50 Duplexsonografien von Patienten ohne zerebrovaskuläre Vorerkrankungen verwendet. Ergebnisse: Der Durchmesser der A. carotis communis betrug bei Patienten mit adulter Pompe-Erkrankung 6,2 ± 0,7 mm (Kontrollen 6,5 ± 0,8 mm, n.s.). Die Durchmesser der intrakraniellen Aa. carotides internae, des M1-Segmentes der Aa. cerebri mediae, der Aa. cerebri anteriores und der A. basilaris waren erweitert. Zusammenfassung: Bei Patienten mit adultem M. Pompe sind die Durchmesser der intrakraniellen hirnversorgenden Gefäße vergrößert. Der Durchmesser der A. carotis communis ist dagegen normal.

  • Open Access

    Pain in adult patients with Pompe disease

    by N. Karabul, M.E. Kruijshaar, A. Schober, D. Güngör, F. Hanisch